GSK plc

GSK · XNYS

CIK 1131399fmd_190D70WXF57BFARSEX070NFW8MManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2015 to Dec 31, 2025, 11 periods

Income Statement · Annual · Millions · GBP
Line item	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	27,889	30,186	30,821	33,754	24,354	24,696	29,324	30,328	31,376	32,667
Cost of revenue	9,290	10,342	10,241	11,863	7,929	8,163	9,554	8,565	9,048	9,017
Gross profit	18,599	19,844	20,580	21,891	16,425	16,533	19,770	21,763	22,328	23,650
Research and development	3,628	4,476	3,893	4,568	4,793	5,019	5,488	6,223	6,401	7,525
Selling, general and administrative	9,366	9,672	9,915	11,402	7,437	7,070	8,372	9,385	11,015	9,088
Operating income	2,598	4,087	5,483	6,961	5,979	4,357	6,433	6,745	4,021	7,932
Interest expense	736	734	798	912	874	769	879	792	669	701
Income before taxes	1,939	3,525	4,800	6,221	5,170	3,599	5,628	6,064	3,477	7,401
Income tax expense	877	1,356	754	953	67	83	707	756	526	1,112
Net income from continuing operations	1,062	2,169	4,046	5,268	5,103	3,516	4,921	5,308	2,951	6,289
Net income	912	1,532	3,623	4,645	5,749	4,385	14,956	4,928	2,575	5,716